Drug General Information
Drug ID
Former ID
Drug Name
UCL-2000 and butabindide
Indication Obesity [ICD9: 278; ICD10:E66] Discontinued in Phase 1 [551995]
University College London
CAS Number
CAS 185213-03-0
Target and Pathway
Target(s) Cholecystokinin receptor type A Target Info Agonist [536122]
Tripeptidyl-peptidase II Target Info Inhibitor [536122]
KEGG Pathway Calcium signaling pathway
Neuroactive ligand-receptor interaction
Insulin secretion
Pancreatic secretion
Reactome Peptide ligand-binding receptors
G alpha (q) signalling eventsR-HSA-983168:Antigen processing: Ubiquitination & Proteasome degradation
WikiPathways GPCRs, Class A Rhodopsin-like
Gastrin-CREB signalling pathway via PKC and MAPK
Peptide GPCRs
GPCR ligand binding
GPCR downstream signaling
Ref 551995Clinical pipeline report, company report or official report of University College London.
Ref 536122Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.

If you find any error in data or bug in web service, please kindly report it to Dr. Wang and Dr. Li.